Effect of trichostatin A and 5-Aza-2′-deoxycytidine on transgene reactivation and epigenetic modification in transgenic pig fibroblast cells

Transgenic technology has greatly facilitated our understanding of gene function, producing pharmaceutical proteins, and generating models for the study of human diseases. However, epigenetic silencing is still the most major limitation. In this study, we employed DNA methyltransferase inhibitor 5-A...

Full description

Saved in:
Bibliographic Details
Published inMolecular and cellular biochemistry Vol. 355; no. 1-2; pp. 157 - 165
Main Authors Kong, Qingran, Wu, Meiling, Wang, Zhenkun, Zhang, Xinmiao, Li, Lu, Liu, Xiangyu, Mu, Yanshuang, Liu, Zhonghua
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.09.2011
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Transgenic technology has greatly facilitated our understanding of gene function, producing pharmaceutical proteins, and generating models for the study of human diseases. However, epigenetic silencing is still the most major limitation. In this study, we employed DNA methyltransferase inhibitor 5-Aza-2′-deoxycytidine (5-Aza-dC) and histone deacetylase inhibitor Trichostatin A (TSA) to study the reactivation of silenced green fluorescent protein (GFP) transgene driven by the cytomegalovirus (CMV) promoter in three fibroblast cell lines from transgenic pigs (tPFs). Analysis showed that porcine fetal fibroblasts (PFF) treated with 0.5 μM 5-Aza-dC for 48 h or 0.25 μM TSA for 24 h had no significantly relevant deaths and no considerably morphological changes. We observed that transgene underwent progressive silencing in a long time course of culture in vitro, and this was correlated with DNA hypermethylation and hypoacetylation of specific histone H3 lysines in the CMV promoter region. Moreover, silenced transgene could be reactivated with 5-Aza-dC or/and TSA treatment by reversing the CMV promoter status of histone hypoacetylation and DNA hypermethylation, and the combination treatment with both agents resulted in a synergistic activation of the transgene, suggesting a cross talk between histone acetylation and DNA methylation. Furthermore, the combination treatment once per 10 days could maintain transgene expression in a high level for more than 60 days by sustaining DNA hypomethylation and histone hyperacetylation. In conclusion, our results suggest that methyltransferase inhibitor 5-Aza-dC and histone deacetylase inhibitor TSA can reactivate silenced transgene and maintain transgene expression by induction of DNA hypomethylation and histone hyperacetylation in the promoter region.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0300-8177
1573-4919
DOI:10.1007/s11010-011-0849-7